Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation

Juan Pablo Alderuccio, Wei Zhao, Amrita Desai, Jeremy Ramdial, Nicolas Gallastegui, Erik Kimble, Macarena I De La Fuente, Muhammad Husnain, Joseph D Rosenblatt, Alvaro J. Alencar, Jonathan H Schatz, Craig Moskowitz, Jennifer Chapman-Fredricks, Francisco Vega, Isildinha Reis, Izidore Lossos

Research output: Contribution to journalArticle

Abstract

Between 11 and 37% of extranodal marginal zone lymphoma (EMZL) patients present with disease involvement in multiple mucosal sites (MMS). We analyzed 405 EMZL patients seen between 1995 and 2017: 265 (65.4%) patients presented with stage I disease, 49 of 309 (15.8%) patients with bone marrow involvement, and 35 of 328 (10.7%) patients with monoclonal gammopathy (MG). Forty-three (10.6%) patients had MMS presentation, which was more frequently seen in patients aged >60 years (55.8%). Five (17.9%) of 28 MMS patients had MG. MMS patients commonly exhibited the International Prognostic Index (IPI) >2 (79.1%), Follicular Lymphoma International Prognostic Index (FLIPI) >2 (39.5%), and Mucosa-Associated Lymphoid Tissue Lymphoma International Prognostic Index (MALT-IPI) 2-3 (60.5%). Both MMS presentation and MG were associated with shorter survival univariately. In multivariable Cox regression models, shorter progression-free survival (PFS) and overall survival (OS) were observed in patients with MMS (hazard ratio [HR] = 3.08 and 2.92, respectively), age ≥60 years (HR = 1.52 and 2.45, respectively), and in patients who failed to attain a complete remission following initial therapy (HR = 3.27 and 2.13, respectively). Elevated lactate dehydrogenase was associated with shorter PFS (HR = 1.92), while anemia (HR = 2.46) was associated with shortened OS. MALT-IPI ≥2 (HR = 2.47 and 4.75), FLIPI >2 (HR = 1.65 and 2.09), and IPI >2 (HR = 2.09 and 1.73) were associated with shorter PFS and OS, respectively. Higher grade transformation (HGT) occurred in 11 (25.6%) MMS patients with a 5-year cumulative incidence of 13.2% (95% CI 4.7-26.1%). EMZL patients with MMS presentation represent a novel clinical subset associated with shorter PFS, OS, and higher incidence of HGT that needs novel therapeutic approaches.

Original languageEnglish (US)
JournalAmerican Journal of Hematology
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation'. Together they form a unique fingerprint.

  • Cite this